US FDA declines to approve Aldeyra's drug for eye disorder

The FDA declined to approve Aldeyra Therapeutics' drug for a type of eye disease, the company said. The decision removes a near-term commercialization opportunity, elevates regulatory and pipeline risk for Aldeyra, and is likely to materially pressure the company's stock and revenue outlook.

Analysis

The FDA declined to approve Aldeyra Therapeutics' drug for a type of eye disease, the company said. The decision removes a near-term commercialization opportunity, elevates regulatory and pipeline risk for Aldeyra, and is likely to materially pressure the company's stock and revenue outlook.